Yttrium-90 ibritumomab tiuxetan consolidation versus rituximab maintenance therapy after induction chemotherapy in patients with indolent non-Hodgkin lymphoma: a single-institution experience

The targeted delivery of radionuclides to tumours holds great promise for diagnosis and treatment of malignant neoplasms. The development of scaffold proteins has significantly simplified the design of targeting agents with desirable properties. This review comprehensively describes the key aspects of the design of radionuclide compounds, including classification of radionuclides, methodology for their attachment to targeting agents and characteristics of these agents that affect their behaviour in the body. Various targeting molecules are compared in terms of their ability to specifically find malignant foci in the body. The most recent achievements of cancer theranostics that aim at increasing the selectivity of antitumour effect are described, such as the fusion of targeting scaffold proteins with the albumin-binding domain and pretargeting. Special attention is paid to the creation of targeted radionanomaterials. Advantages and disadvantages of different strategies are analyzed and approaches for improving the delivery to tumours and for minimizing the undesirable impact on healthy organs and tissues are proposed. Particular emphasis is placed on the results of studies published in 2020–2021 that have not yet been covered by reviews. The bibliography includes 191 references.

show abstract

Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review

Fallahi

Zerangian

Deravi

et al. 2024

CCTR

View full text Add to dashboard Cite

Non-Hodgkin lymphoma (NHL) occurs in the lymphatic system because of lymphocytes tumor. This type of tumor has a high death rate among patients. In recent years, a lot of progress has been made based on under-standing its exact biology; several treatment methods have been developed. Many patients are cured by a combination of different chemotherapies, despite their toxic effects. In recent years, despite various studies on monoclonal antibodies for non-Hodgkin lymphoma, there have been no narrative articles in this field. Therefore, combining monoclonal antibodies with chemotherapy is successful as they reduce the toxic side effects of chemotherapies. These antibodies can target specific cellular pathways of the immune system lead-ing to limitation of cancer progression. In this article, various types of monoclonal antibodies, their underly-ing mechanisms of action, as well as their effects on patients with different phases and types of Non-Hodgkin lymphoma have been reviewed for a better understanding.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Yttrium-90 ibritumomab tiuxetan consolidation versus rituximab maintenance therapy after induction chemotherapy in patients with indolent non-Hodgkin lymphoma: a single-institution experience

Abstract: View related articles View Crossmark data Citing articles: 1 View citing articles Yttrium-90 ibritumomab tiuxetan consolidation versus rituximab maintenance therapy after induction chemotherapy in patients with indolent non-Hodgkin lymphoma: a single-institution experience

Cited by 3 publications

References 29 publications

Ibritumomab tiuxetan/ibritumomab tiuxetan-Y-90/rituximab

Ibritumomab tiuxetan/ibritumomab tiuxetan-Y-90/rituximab

Targeted nuclear medicine. Seek and destroy

Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review

Contact Info

Product

Resources

About